

Influence of mTOR and ERK 1/2 pathways on ECE2015 the IGF-1 negative feedback in GH secreting pituitary adenoma cell line




Carmelina Di Pasquale, Mariaenrica Bellio, Erica Gentilin, Teresa Gagliano, Simona Falletta, Katiuscia Benfini, Maria Rosaria Ambrosio, Ettore degli Uberti, Maria Chiara Zatelli.

Department of Medical Science, Section of Endocrinology and Internal Medicine, University of Ferrara, Italy

Background: Gigantism and Acromegaly are the main consequences of GH excess, mainly due to a pituitary adenoma. Surgery is the first therapeutic option, but also medical therapy is employed, being mostly represented by somatostatin analogues (SSA), that reduce both tumor mass and GH hypersecretion. However about 10% of patients is resistant to SSA.

PI3K/Akt/mTOR pathway, activated by growth-factors such as IGF-1, is important in regulating many cellular processes.

Alm: To understand whether PI3K/Akt/mTOR and ERK 1/2 pathways can influence IGF-1 feed-back in GH secreting pituitary adenoma cell line, we employed three inhibitors: Everolimus (mTOR inhibitor), NVP-BEZ235 (mTOR and PI3K inhibitor) and SCH772984 (ERK 1/2 inhibitor), evaluating their effects in presence or in absence of IGF-1.




Material and methods: Cell viability and GH secretion assays

have been performed in the GH3 cell line (rat GH-secreting pituitary adenoma cell line).







Conclusions: These data indicate that IGF-1 is important in regulating proliferation and GH secretion in GH3 cells. mTOR blockade reduces viability without affecting GH secretion. ERK 1/2 affects secretion but not IGF-1 negative feed-back. In conclusion, our data suggest that mTOR and ERK 1/2 pathways are not involved in IGF-1 feed-back on GH secretion.





